RDY vs. VRTX: Dr. Reddy's Laboratories vs. Vertex Pharmaceuticals Stock Comparison

Company Profile

Dr. Reddy's Laboratories (RDY) and Vertex Pharmaceuticals (VRTX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but RDY is classified in Pharmaceuticals while VRTX is classified in Biotechnology.

Vertex Pharmaceuticals (VRTX) trades as ordinary local shares, while Dr. Reddy's Laboratories (RDY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Dr. Reddy's Laboratories (RDY) at 7.34% and Vertex Pharmaceuticals (VRTX) at 20.80% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Vertex Pharmaceuticals (VRTX) at 30.70% keeps the most of each sales dollar — above its industry’s net margin range — and Dr. Reddy's Laboratories (RDY) at 8.49% also retains a top-quartile share.

Vertex Pharmaceuticals (VRTX) at 35.57% operates in the top operating margin quartile, ahead of Dr. Reddy's Laboratories (RDY) at 14.73%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Dr. Reddy's Laboratories (RDY) at 3.19% and Vertex Pharmaceuticals (VRTX) at 8.90% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Dr. Reddy's Laboratories (RDY) reports EPS growth of -24.14%, ranked against its industry; Vertex Pharmaceuticals (VRTX) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Dr. Reddy's Laboratories (RDY) at 1.93 and Vertex Pharmaceuticals (VRTX) at 2.34 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Dr. Reddy's Laboratories (RDY) at 0.19 and Vertex Pharmaceuticals (VRTX) at 0.31 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Vertex Pharmaceuticals (VRTX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Dr. Reddy's Laboratories (RDY) reports a yield of 55.06%, ranking against industry peers normally.

Vertex Pharmaceuticals (VRTX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Dr. Reddy's Laboratories (RDY) reports a payout of 22.72%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both Dr. Reddy's Laboratories (RDY) at 41.42 and Vertex Pharmaceuticals (VRTX) at 35.21 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

Dr. Reddy's Laboratories (RDY) at 0.04 sits in the cheaper P/S ratio quartile while Vertex Pharmaceuticals (VRTX) at 10.71 prices around its industry’s middle — RDY costs less per dollar of sales, though read it alongside growth and margins.

Both look rich against book: Vertex Pharmaceuticals (VRTX) at 6.63 sits in the upper P/B ratio quartile, and Dr. Reddy's Laboratories (RDY) at 18.16 prices even higher, above its industry range.

Valuation Metrics